Chau Dang

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions
    Chau T Dang
    Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Expert Rev Anticancer Ther 6:427-36. 2006
  2. ncbi request reprint Potential role of selective COX-2 inhibitors in cancer management
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 16:30-6. 2002
  3. ncbi request reprint Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg
    Chau Dang
    Department of Medicine, Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:51-8. 2006
  4. doi request reprint The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 713, New York, NY 10021, USA
    J Clin Oncol 26:1216-22. 2008
  5. doi request reprint Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 8:418-24. 2008
  6. ncbi request reprint Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:5754-61. 2004
  7. pmc Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:2982-8. 2010
  8. ncbi request reprint Risk models for neutropenia in patients with breast cancer
    Chau T Dang
    Breast Cancer Medical Service, Memorial Sloan Kettering, Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:14-20. 2003
  9. ncbi request reprint Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Am Geriatr Soc 54:925-31. 2006
  10. doi request reprint A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011

Detail Information

Publications22

  1. ncbi request reprint Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions
    Chau T Dang
    Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Expert Rev Anticancer Ther 6:427-36. 2006
    ..Newer agents are on the horizon...
  2. ncbi request reprint Potential role of selective COX-2 inhibitors in cancer management
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 16:30-6. 2002
    ..Clinical trials using targeted inhibitors of COX-2 will be critical in determining if COX-2 is a viable molecular target in cancer management...
  3. ncbi request reprint Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg
    Chau Dang
    Department of Medicine, Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:51-8. 2006
    ..Thus, taxanes should be incorporated into the adjuvant treatment of breast cancer. To date, the available data do not allow one to select a single best taxane, schedule, or overall regimen...
  4. doi request reprint The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 713, New York, NY 10021, USA
    J Clin Oncol 26:1216-22. 2008
    ..The primary end point was cardiac safety, and the secondary end points were time to recurrence and overall survival...
  5. doi request reprint Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 8:418-24. 2008
    ..Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility...
  6. ncbi request reprint Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:5754-61. 2004
    ..The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival...
  7. pmc Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:2982-8. 2010
    ..We conducted a pilot study of dose-dense AC followed by PT plus lapatinib (PTL) followed by trastuzumab plus lapatinib (TL)...
  8. ncbi request reprint Risk models for neutropenia in patients with breast cancer
    Chau T Dang
    Breast Cancer Medical Service, Memorial Sloan Kettering, Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:14-20. 2003
    ..These findings could lead to changes in how early-stage breast cancer is managed...
  9. ncbi request reprint Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Am Geriatr Soc 54:925-31. 2006
    ..To report on the longitudinal cognitive functioning of older women receiving adjuvant chemotherapy for breast cancer...
  10. doi request reprint A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
    ..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer...
  11. ncbi request reprint A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Am Geriatr Soc 54:1119-24. 2006
    ..To examine the toxicity experienced by a cohort of older women receiving adjuvant chemotherapy for breast cancer and the longitudinal effect on their functional status and quality of life (QOL)...
  12. pmc Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer
    Ayca Gucalp
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 11:306-11. 2011
    ..We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)(-) and progesterone receptor (PR)(-) metastatic breast cancer (MBC)...
  13. ncbi request reprint Current status of the taxanes as adjuvant therapy for breast cancer
    Clifford Hudis
    Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, MSKCC, 1275 York Avenue, New York, NY, USA
    Breast 16:S132-5. 2007
    ..These trials are generally positive but do not clearly identify a single best or ideal regimen for all patients. This paper reviews the available data in this area of clinical research...
  14. ncbi request reprint Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 98:343-8. 2006
    ..This longitudinal prospective study describes the older breast cancer patient's perception of the cognitive impact of adjuvant chemotherapy...
  15. doi request reprint Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Departments of Radiology, Biostatistics, and Renal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:628-33. 2010
    ..We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)...
  16. doi request reprint Adjuvant taxanes: more to the story
    Devika Gajria
    Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Breast Cancer 10:S41-9. 2010
    ..In this overview, we will review some of the key trials that have advanced the standard of care in the adjuvant setting with regard to various chemotherapy combinations...
  17. ncbi request reprint Cardiac dysfunction associated with trastuzumab
    Karen Lisa Smith
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Drug Saf 5:619-29. 2006
    ..This article reviews the cardiac toxicity findings in key trastuzumab clinical trials and clinical characteristics of trastuzumab-associated cardiac toxicity...
  18. ncbi request reprint Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4062-7. 2004
    ....
  19. pmc A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Maura N Dickler
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:7878-83. 2008
    ..To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway...
  20. ncbi request reprint Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group
    Clifford A Hudis
    Breast Dis 21:3-13. 2004
  21. pmc Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 27:6117-23. 2009
    ..Dose-dense (dd) AC followed by paclitaxel (P) is superior to the same regimen given every third week. Herein, we report the early cardiac safety of three sequential studies of ddAC alone or with bevacizumab (B)...
  22. ncbi request reprint The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma
    Rose Lai
    Department of Epidemiology and Biostatistics, McMaster University Hamilton Regional Cancer Center, Hamilton, Ontario, Canada
    Cancer 101:810-6. 2004
    ..Few studies have compared the risk of central nervous system (CNS) metastases in patients treated with or without trastuzumab...